drugset / Trial / NCT00162461
Evaluation of CYP2C9 Activity
Unknown
1200 enrolled
Hadassah Medical Organization
United States - Israel Binational Science Foundation · collab
NaSingle-groupOpen-labelOther
Summary
The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9. The purpose of the present study is: 1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity 2. To correlate phenytoin metabolic ratio with CYP2C9 genotype 3. To study the frequency distribution of CYP2C9 activity in-vivo
Timeline
- Start
- 1998-08
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Phenytoin | Unknown | 300 mg | — |
Indications
No indication recorded.